NeurologyLive® Friday 5 — May 13, 2022

Author(s):

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 13, 2022.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Peers & Perspectives: Relapsing-Remitting Multiple Sclerosis and Impact on Quality of Life

Ahmed Obeidat, MD, PhD, and Annette Okai, MD, FAAN, experts in multiple sclerosis, discuss the impact of relapsing-remitting disease on the quality of life of patients and caregivers in the opening episode of this NeurologyLive^® Peers & Perspectives series, "Optimizing Treatment of Relapsing-Remitting Multiple Sclerosis with Oral Therapies."

Relapsing-Remitting Multiple Sclerosis (RRMS) and Impact on Quality of Life

2: Rapid Progress in ALS: A Reflection of Advances in Neuromuscular Disorder Care

With a burst of activity in recent months, the pipeline of development for amyotrophic lateral sclerosis has proven to be a miniature likeness of the wider progress being made in the care and management of neuromuscular disorders.

3: NeuroVoices: Amy Brin, MSN, MA, PCNS-BC, on Her New Role on an NIH NANDS Council

The chief executive officer of the Child Neurology Foundation discussed how her background in pediatric neurology will be used in a newly appointed NIH council position and the hot topics on the minds of pediatric neurologists across the globe.

4: Understanding How Nonmotor Symptoms Worsens Parkinson Disease Condition: Jill Farmer, DO, MPH

The assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute discussed the need to understand the chemical markers that trigger nonmotor symptoms of Parkinson disease.

5: Peer Exchange: Acute Versus Preventative Treatment of Migraine

In Episode 7 of this NeurologyLive^® Peer Exchange series, "Optimal Management of Acute and Preventive Migraine," Julio R. Vieira, MD, speaks with the panel to define acute versus preventive treatment for migraine and highlights the differences in goals of therapy for each.